MediWound (MDWD) Competitors $17.60 +0.21 (+1.21%) Closing price 04:00 PM EasternExtended Trading$17.58 -0.02 (-0.11%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDWD vs. OCS, ORIC, NUVB, SION, NAGE, VALN, CRMD, IOVA, PROK, and NRIXShould you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Oculis (OCS), Oric Pharmaceuticals (ORIC), Nuvation Bio (NUVB), Sionna Therapeutics (SION), Niagen Bioscience (NAGE), Valneva (VALN), CorMedix (CRMD), Iovance Biotherapeutics (IOVA), ProKidney (PROK), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry. MediWound vs. Its Competitors Oculis Oric Pharmaceuticals Nuvation Bio Sionna Therapeutics Niagen Bioscience Valneva CorMedix Iovance Biotherapeutics ProKidney Nurix Therapeutics MediWound (NASDAQ:MDWD) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment. Do analysts recommend MDWD or OCS? MediWound currently has a consensus target price of $32.25, indicating a potential upside of 83.24%. Oculis has a consensus target price of $35.67, indicating a potential upside of 99.81%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to MDWD or OCS? In the previous week, Oculis had 7 more articles in the media than MediWound. MarketBeat recorded 14 mentions for Oculis and 7 mentions for MediWound. Oculis' average media sentiment score of 0.22 beat MediWound's score of -0.37 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Oculis 4 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals believe in MDWD or OCS? 46.8% of MediWound shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger earnings and valuation, MDWD or OCS? MediWound has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediWound$20.22M9.41-$30.22M-$2.64-6.67Oculis$780K999.14-$97.43M-$2.64-6.76 Is MDWD or OCS more profitable? MediWound has a net margin of -142.18% compared to Oculis' net margin of -13,788.70%. Oculis' return on equity of -92.95% beat MediWound's return on equity.Company Net Margins Return on Equity Return on Assets MediWound-142.18% -96.71% -39.73% Oculis -13,788.70%-92.95%-70.03% Which has more risk & volatility, MDWD or OCS? MediWound has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. SummaryMediWound beats Oculis on 8 of the 15 factors compared between the two stocks. Get MediWound News Delivered to You Automatically Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDWD vs. The Competition Export to ExcelMetricMediWoundMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$190.26M$2.80B$5.82B$9.74BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-6.6722.6131.1525.97Price / Sales9.41751.86475.57123.18Price / CashN/A173.2237.1558.38Price / Book9.465.869.116.39Net Income-$30.22M$31.83M$3.26B$265.66M7 Day Performance-2.76%1.80%2.11%1.98%1 Month Performance-14.10%4.36%5.12%1.33%1 Year Performance-6.23%11.44%31.25%21.15% MediWound Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDWDMediWound1.5012 of 5 stars$17.60+1.2%$32.25+83.2%-7.2%$190.26M$20.22M-6.6780Analyst DowngradeOCSOculis3.2721 of 5 stars$17.97-1.3%$35.33+96.6%+49.1%$795.09M$780K-6.812News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst ForecastORICOric Pharmaceuticals4.774 of 5 stars$9.20-0.4%$18.57+101.9%-1.2%$787.47MN/A-4.9280NUVBNuvation Bio2.3301 of 5 stars$2.24-2.8%$7.33+228.1%-2.3%$782.60M$7.87M-3.5560SIONSionna Therapeutics1.9525 of 5 stars$20.03+13.4%$38.50+92.2%N/A$779.68MN/A0.0035NAGENiagen Bioscience1.3517 of 5 stars$9.82+0.9%$13.42+36.7%N/A$776M$99.60M46.76120VALNValneva2.6377 of 5 stars$8.50-6.7%$15.50+82.4%+41.3%$775.21M$183.52M-7.14700Trending NewsAnalyst ForecastAnalyst RevisionGap UpTrading HaltedHigh Trading VolumeCRMDCorMedix2.7204 of 5 stars$10.07-2.5%$16.71+66.0%+170.7%$771.12M$43.47M13.4330IOVAIovance Biotherapeutics4.8463 of 5 stars$1.97-6.6%$11.90+504.1%-78.5%$763.51M$164.07M-1.60500Analyst ForecastShort Interest ↓PROKProKidney3.7833 of 5 stars$2.26-12.7%$6.25+176.5%-2.9%$758.09M$80K-3.773News CoverageShort Interest ↓NRIXNurix Therapeutics2.665 of 5 stars$9.65-1.9%$28.87+199.1%-59.6%$752.26M$54.55M-3.70300 Related Companies and Tools Related Companies Oculis Alternatives Oric Pharmaceuticals Alternatives Nuvation Bio Alternatives Sionna Therapeutics Alternatives Niagen Bioscience Alternatives Valneva Alternatives CorMedix Alternatives Iovance Biotherapeutics Alternatives ProKidney Alternatives Nurix Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDWD) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access